Evidence map›Paper›PMID 37518267›Full record

ArticleExperimental animals2024

Time course of histopathology of bleomycin-induced pulmonary fibrosis using an intratracheal sprayer in mice.

Hideyuki Kobayashi, Ayami Tachi, Sumihiko Hagita

Open access · diamondAbstract read
In one paragraph

Article in Experimental animals, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hideyuki KobayashiTokyo New Drug Research Laboratories, Pharmaceutical Division, Kowa Company, Ltd., 2-17-43 Noguchicho, Higashimurayama, Tokyo 189-0022, Japan.
Ayami TachiTokyo New Drug Research Laboratories, Pharmaceutical Division, Kowa Company, Ltd., 2-17-43 Noguchicho, Higashimurayama, Tokyo 189-0022, Japan.
Sumihiko HagitaTokyo New Drug Research Laboratories, Pharmaceutical Division, Kowa Company, Ltd., 2-17-43 Noguchicho, Higashimurayama, Tokyo 189-0022, Japan.
Kowa (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a poor prognosis disease that affects approximately 5 million people worldwide, and the detailed mechanisms underlying the pathogenesis of IPF remain unclear. Bleomycin-induced pulmonary fibrosis has been widely used as a representative animal model of IPF that induces fibrosis in lung tissue. The lungs of rodent consist of five lobes and each bronchus enters each lobe of the lung at a different bifurcation angle, path length, and diameter. The method of administration of bleomycin is considered as important thing to establish appropriate animal models. We conducted a time-dependent histopathological study to examine how pulmonary fibrosis develops in each lung lobe when bleomycin was intratracheally sprayed in ICR mice. And we then explored the suitable points for evaluation of anti-fibrotic agents in this model. As a result, we found that homogeneous fibrosis was induced in the 5 lobes of the lungs following initial inflammation. The expression of transforming growth factor (TGF)-β1 and phospho-Smad2 (pSmad2) was observed from Day 1, and their positivity increased until Day 21. In conclusion, we have observed a detailed time course of histological changes in bleomycin-induced pulmonary fibrosis in ICR mice using the aerosolization technique. We found that our protocol can induce a highly homogeneous lesion in the lung and that the most suitable time point to assess anti-fibrotic agents is 14 days after treatment in this model.

Indexed as

Pulmonary FibrosisAnimalsAntifibrotic AgentsBleomycinDisease Models, AnimalFibrosisHumansLungMiceMice, Inbred C57BLMice, Inbred ICRTransforming Growth Factor beta1Antifibrotic AgentsBleomycinTransforming Growth Factor beta1bleomycinhistopathologyintratracheal aerosolizationmicepulmonary fibrosis

Identifiers

PMID37518267
PMCPMC10877150
OpenAlexW4385297830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.